Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 12, 2025 01:00 ET | Source: Biogen Inc.

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activityDZP showed consistent improvements in fatigue,...
October 04, 2023 03:00 ET | Source: Spherix Global Insights

In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK’s Benlysta and AstraZeneca’s Saphnelo for the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus, According to Spherix Global In

Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the...
June 15, 2021 08:00 ET | Source: Scipher Medicine Corporation

Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test

Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in an independent validation cohort PrismRA demonstrates a more...
May 28, 2019 08:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting

New data from ongoing Phase 2 open-label extension of lenabasum in systemic sclerosis and open-label extension data in dermatomyositis studies to be presentedPresentation includes data from some...
June 14, 2017 09:00 ET | Source: Horizon Pharma plc

Epidemiologic Study Findings Show Over 400 Percent Increase in Gout Patient Hospitalizations Since 1993

MADRID, Spain, June 14, 2017 (GLOBE NEWSWIRE) -- Results from a new study to be presented tomorrow at the Annual European Congress of Rheumatology (EULAR) 2017 show a 410 percent increase in...
May 09, 2016 16:05 ET | Source: Prothena Corporation plc

Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory Diseases, at EULAR 2016

DUBLIN, Ireland, May 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...